Quantitative RAR beta 2 hypermethylation: A promising prostate cancer marker

• Type: Article in International Scientific Journal
• Date: 2004

Authors

Carmen Jeronimo (Author) Other; henrique, rmf (Author) ICBAS; Hoque, MO (Author) Other; Ribeiro, FR (Author) Other; Oliveira, J (Author) Other; Fonseca, D (Author) Other; Manuel R Teixeira (Author) ICBAS; Lopes, C (Author) Other; Sidransky, D (Author) Other

Journal

Title: Clinical Cancer Research

Vol. 10

Pages: 4010-4014

ISSN: 1078-0432

Publisher: American Association for Cancer Research

Indexing

ISI Web of Knowledge - 100 Citations

Scopus - 106 Citations

Other information

Authenticus ID: P-000-9Y8

DOI: 10.1158/1078-0432.ccr-03-0643

Abstract (EN): Retinoic acid receptor beta2 (RARbeta2) is a tumor suppressor gene frequently hypermethylated in several human neoplasms. To further characterize this epigenetic alteration in prostate cancer progression, we examined tumor tissue from 118 patients with prostate carcinoma (PCa), 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and nonneoplastic prostate tissue from 30 patients with benign prostate hyperplasia (BPH), using quantitative methylation-specific PCR. We found RARbeta2 hypermethylation in 97.5% of PCa, 94.7% of HGPIN, and 23.3% of BPH. Methylation levels were significantly higher in PCa compared with HGPIN and BPH (P < 0.00001). By establishing an empiric cutoff value, we were able to discriminate between neoplastic and non-neoplastic tissue, with 94.9% sensitivity and 100% specificity. Moreover, RARbeta2 methylation levels correlated with higher pathological stage (r = 0.30, P = 0.0009). This quantitative assay represents a novel and promising molecular marker that may augment current approaches for prostate cancer detection.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 5